Symbiotec Pharmalab IPO Day 2 Subscription Status: 1.14x Subscribed; GMP at ₹409
Symbiotec Pharmalab’s IPO was subscribed 1.14 times on Day 2, as of the morning (9:00 a.m. to 11:00 a.m. IST) on 25 August 2026, compared with 0.85x at the end of Day 1. Small Non-Institutional Investors (sNIIs) led at 2.25x, while employee demand reached 2.05x. The issue remains open until 27 August. The latest available Grey Market Premium (GMP) reading was around ₹409, although trackers differed materially.
| Metric | Latest update |
| Bidding day | Day 2 |
| Data status | Morning (9:00 a.m. to 11:00 a.m. IST) on 25 August 2026 |
| Overall subscription | 1.14x |
| QIB subscription | 0.56x |
| NII subscription | 1.49x |
| Retail subscription | 1.33x |
| Employee subscription | 2.05x |
| Current GMP | Around ₹409 |
| GMP percentage | About 41.4% |
| Indicative price | ₹1,397 |
| Closing date | 27 August 2026 |
Symbiotec Pharmalab IPO Day 2 Subscription Status
The Day 2 subscription data showed broader participation than at the end of the opening session. Non-Institutional Investors (NIIs), retail investors, and employees were all above 1x, while Qualified Institutional Buyers (QIBs) remained below full subscription.
| Investor category | Day 2 | Day 1 close | Change |
| Qualified Institutional Buyers (QIBs) | 0.56x | 0.37x | +0.19x |
| Non-Institutional Investors (NIIs) | 1.49x | 1.10x | +0.39x |
| Retail Individual Investors | 1.33x | 1.01x | +0.32x |
| Employees | 2.05x | 1.65x | +0.40x |
| Overall | 1.14x | 0.85x | +0.29x |
Within the NII portion, small NIIs were subscribed 2.25x, compared with 1.10x for the larger NII segment. This made small NII demand the highest multiple among the reported investor subcategories in the verified morning snapshot.
Subscription multiples measure shares bid for relative to shares reserved, not the number of unique applicants.
How Subscription Changed From Day 1
Symbiotec Pharmalab IPO moved from 0.85x at the Day 1 close to 1.14x on Day 2, an absolute increase of 0.29x.
The strongest movement came from the small NII segment, which increased from 1.66x on Day 1 to 2.25x. Employee subscription rose from 1.65x to 2.05x, while total NII demand increased from 1.10x to 1.49x. Retail demand also moved higher from 1.01x to 1.33x.
QIB participation improved from 0.37x to 0.56x but remained the only major investor category below 1x. Institutional bids often build later in the bidding period, although that does not mean they will necessarily do so in this IPO.
Symbiotec Pharmalab IPO GMP Today and Estimated Listing Price
The freshest widely reported Symbiotec Pharmalab IPO GMP reading was around ₹409 per share during the morning of 25 August 2026.
At the upper price band of ₹988:
Indicative price = ₹988 + ₹409 = ₹1,397
GMP percentage = ₹409 ÷ ₹988 × 100 = about 41.4%
The ₹409 reading was higher than an earlier available reference of about ₹345, implying an increase of ₹64. However, GMP trackers were not fully aligned. Other available readings on 25 August were around ₹340 to ₹385.
Because the grey market is unofficial and unregulated, these differences are important. GMP is not published by the Securities and Exchange Board of India (SEBI), National Stock Exchange of India (NSE), or BSE Limited (BSE), and it can change quickly. The ₹1,397 figure is indicative only and does not guarantee the actual listing price or gains.
What Stands Out in Today’s Bidding
The first notable signal is that demand became broader between the Day 1 close and the Day 2 morning update. Retail, NII, and employee categories were all above full subscription, while the overall issue crossed 1x.
Second, small NII demand remained the highest reported subcategory at 2.25x, suggesting that the increase was not being driven evenly across every investor segment.
Two limitations remain. QIB subscription was still below 1x, leaving the institutional picture incomplete. Also, the roughly 41% GMP indicated by the ₹409 reading was far stronger than the 1.14x formal subscription multiple. The two measures capture different things, and neither establishes fair valuation, business quality, or future returns.
IPO Details Retail Investors Need
| IPO detail | Information |
| Price band | ₹938 to ₹988 per share |
| Lot size | 15 shares |
| Minimum retail investment | ₹14,820 at upper band |
| Issue size | About ₹1,757 crore |
| Fresh issue | ₹150 crore |
| Offer for Sale (OFS) | About ₹1,607 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 27 August 2026 |
| Expected listing date | 1 September 2026 |
| Exchange | NSE and BSE |
Most of the IPO is an Offer for Sale (OFS), so the proceeds from that portion will go to the selling shareholders rather than to Symbiotec Pharmalab.
Brief Company and Financial Context
Symbiotec Pharmalab manufactures Active Pharmaceutical Ingredients (APIs), nutritional ingredients, and specialised pharmaceutical products, with international markets contributing a substantial share of revenue. Total revenue rose from about ₹755.98 crore in FY2025 to ₹872.26 crore in FY2026, while Profit After Tax (PAT) increased from ₹96.79 crore to ₹109.90 crore.
Of the ₹150 crore fresh issue, about ₹112.5 crore is intended for repayment or prepayment of borrowings, with the balance available for general corporate purposes. One material consideration is product concentration, with the company’s top five products contributing a sizeable share of revenue.
What Happens Next
The IPO has two bidding days remaining and is scheduled to close on 27 August 2026. On the closing day, the main numbers to monitor will be overall subscription growth, QIB participation, whether NII and retail demand continues to rise, and whether GMP remains near its current range or changes materially.
Frequently Asked Questions (FAQs)
Q: How many times was the Symbiotec Pharmalab IPO subscribed on Day 2?
A: Symbiotec Pharmalab IPO was subscribed 1.14x overall as of the morning (9:00 a.m. to 11:00 a.m. IST) on 25 August 2026. NII demand was 1.49x, retail was 1.33x, employees were at 2.05x, and QIBs were at 0.56x.
Q: How did Symbiotec Pharmalab IPO demand change from Day 1 to Day 2?
A: Overall subscription increased from 0.85x at the Day 1 close to 1.14x in the verified Day 2 morning snapshot, an absolute rise of 0.29x. NII, retail, employee, and QIB subscriptions all increased.
Q: What is the Symbiotec Pharmalab IPO GMP today?
A: The freshest widely reported GMP reading was around ₹409 per share during the morning of 25 August 2026. Other trackers showed readings around ₹340 to ₹385, so grey-market estimates were not fully aligned.
Q: What listing price does the current Symbiotec Pharmalab IPO GMP indicate?
A: A ₹409 GMP added to the ₹988 upper price band gives an indicative price of about ₹1,397 per share. GMP is unofficial, can change quickly, and does not guarantee the actual listing price.
Q: Does high subscription or GMP guarantee a premium listing?
A: No. Subscription measures formal bidding demand, while GMP is an unofficial grey-market sentiment indicator. Neither guarantees a premium listing, fair valuation, strong business performance, or future investment returns.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
